LVTX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 9.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $9,944,164.16
LAVA Therapeutics Share Price & Price History
Current Price: $1.74
Price Change: +0.30 (1.20%)
As of 12/5/2025 01:00 AM ET
LAVA Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/17/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 1,181,131 | $1.47 | $1,736,262.57 | 2,947,781 |  |
| 10/16/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 690,239 | $1.49 | $1,028,456.11 | 4,128,912 | |
| 10/14/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 227,341 | $1.51 | $343,284.91 | 5,019,151 | |
| 10/13/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 47,686 | $1.54 | $73,436.44 | 5,246,492 | |
| 10/10/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 49,869 | $1.55 | $77,296.95 | 5,294,178 | |
| 10/9/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 48,169 | $1.56 | $75,143.64 | 5,344,047 | |
| 10/8/2025 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 28,954 | $1.57 | $45,457.78 | 5,392,216 | |
| 9/19/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 2,370,533 | $1.40 | $3,318,746.20 | | |
| 9/19/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 532,870 | $1.40 | $746,018.00 | | |
| 9/18/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 366,111 | $1.44 | $527,199.84 | 2,370,533 | |
| 9/18/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 228,791 | $1.44 | $329,459.04 | 532,870 | |
| 9/17/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 362,806 | $1.49 | $540,580.94 | 2,736,644 | |
| 9/17/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 226,726 | $1.49 | $337,821.74 | 761,661 | |
| 9/16/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 307,707 | $1.53 | $470,791.71 | 3,099,450 | |
| 9/16/2025 | Versant Venture Capital Vi, L. | Major Shareholder | Sell | 192,293 | $1.53 | $294,208.29 | 988,387 | |
| 10/20/2015 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 1,000,000 | $1.46 | $1,460,000.00 | 1,947,781 | |
| 10/15/2015 | Gilde Healthcare Cooperatieve | Major Shareholder | Sell | 200,000 | $1.51 | $302,000.00 | 4,819,151 | |
LAVA Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Citadel Advisors LLC | 53,308 | $83K | 0.0% | -23.4% | 0.203% |  |
| 11/14/2025 | Shay Capital LLC | 2,548,730 | $3.98M | 0.3% | N/A | 9.689% | |
| 8/16/2025 | Lepercq De Neuflize Asset Management LLC | 31,000 | $41K | 0.0% | +34.8% | 0.118% | |
| 8/15/2025 | Rangeley Capital LLC | 27,073 | $36K | 0.0% | N/A | 0.103% | |
| 8/11/2025 | BML Capital Management LLC | 1,970,610 | $2.60M | 2.0% | +0.5% | 7.491% | |
| 5/14/2025 | Bruce & Co. Inc. | 521,874 | $0.66M | 0.2% | -32.4% | 1.984% | |
| 5/13/2025 | Lepercq De Neuflize Asset Management LLC | 23,000 | $29K | 0.0% | N/A | 0.087% | |
| 5/8/2025 | XTX Topco Ltd | 24,307 | $31K | 0.0% | N/A | 0.092% | |
| 5/7/2025 | BML Capital Management LLC | 1,960,610 | $2.49M | 1.9% | N/A | 7.453% | |
| 2/17/2025 | Two Sigma Investments LP | 48,772 | $46K | 0.0% | -52.5% | 0.186% | |
| 2/17/2025 | Sanofi | 1,919,455 | $1.83M | 1.0% | N/A | 7.301% | |
| 2/17/2025 | Sphera Funds Management LTD. | 126,328 | $0.12M | 0.0% | -13.7% | 0.481% | |
| 2/17/2025 | BNP Paribas Financial Markets | 41,800 | $40K | 0.0% | N/A | 0.159% | |
| 11/20/2024 | Virtu Financial LLC | 19,103 | $32K | 0.0% | N/A | 0.075% | |
| 11/15/2024 | Sphera Funds Management LTD. | 146,457 | $0.24M | 0.0% | -60.2% | 0.000% | |
| 11/14/2024 | Walleye Capital LLC | 14,762 | $25K | 0.0% | -42.5% | 0.000% | |
| 10/8/2024 | Pathway Financial Advisors LLC | 102,500 | $0.17M | 0.0% | +70.8% | 0.404% | |
| 8/12/2024 | XTX Topco Ltd | 30,807 | $55K | 0.0% | N/A | 0.122% | |
| 7/24/2024 | Pathway Financial Advisors LLC | 60,000 | $0.11M | 0.0% | +328.6% | 0.000% | |
| 4/10/2024 | Pathway Financial Advisors LLC | 14,000 | $47K | 0.0% | N/A | 0.000% | |
| 5/12/2023 | Bruce & Co. Inc. | 671,874 | $1.12M | 0.3% | +571.9% | 2.650% | |
| 2/10/2023 | PNC Financial Services Group Inc. | 50,000 | $0.18M | 0.0% | N/A | 0.197% | |
| 2/1/2023 | Bank of Montreal Can | 89,600 | $0.53M | 0.0% | N/A | 0.353% | |
| 11/14/2022 | UBS Oconnor LLC | 75,000 | $0.34M | 0.0% | N/A | 0.296% | |
| 10/28/2022 | Silverarc Capital Management LLC | 610,809 | $2.79M | 0.9% | N/A | 2.409% | |
| 8/16/2022 | DAFNA Capital Management LLC | 128,335 | $0.38M | 0.1% | -7.9% | 0.506% | |
| 8/15/2022 | Nantahala Capital Management LLC | 322,980 | $0.95M | 0.0% | -3.3% | 1.274% | |
| 2/14/2022 | Point72 Asset Management L.P. | 119,152 | $0.66M | 0.0% | -3.8% | 0.470% | |
Data available starting January 2016
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Read More on LAVA Therapeutics
Volume
N/A
Average Volume
124,342 shs
Market Capitalization
$45.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.5
Who are the company insiders with the largest holdings of LAVA Therapeutics?
Who are the major institutional investors of LAVA Therapeutics?
Which institutional investors are selling LAVA Therapeutics stock?
During the last quarter, LVTX stock was sold by these institutional investors:
- Equitec Proprietary Markets LLC
During the last year, company insiders that have sold LAVA Therapeutics company stock include:
- Gilde Healthcare Cooperatieve (Major Shareholder)
- Versant Venture Capital Vi, L (Major Shareholder)
Learn More investors selling LAVA Therapeutics stock.
